Zoekresultaten - Portaal voor medische datamodellen (MDM-portaal)

Zoekresultaten filteren
Datamodellen selecteren

Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

4 Zoekresultaten.

Genetic Screening For HLA-B5701 in Patients with HIV Serious Adverse Events NCT00340080 - Genetic Screening For HLA-B5701 Serious Adverse Events NCT00340080

- 25-04-17 - 1 Formulier, 1 Itemgroep, 55 Data-elementen, 1 Taal

Itemgroep: Serious Adverse Events

NCT00340080 / VIIV-CNA106030 A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity Assessment: Serious Adverse Events Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus, Phase: 4, Clinical Study ID: CNA106030, Sponsor: ViiV

Genetic Screening For HLA-B5701 in Patients with HIV Non-serious Adverse Events NCT00340080 - Genetic Screening For HLA-B5701 Non-serious Adverse Events NCT00340080

- 25-04-17 - 1 Formulier, 1 Itemgroep, 10 Data-elementen, 1 Taal

Itemgroep: Non-serious Adverse Events

NCT00340080 / VIIV-CNA106030 A phase IV, randomised, multicentre, double-blind, study to evaluate the clinical utility of prospective genetic screening (HLA-B*5701) for susceptibility to abacavir hypersensitivity Assessment: Non-serious Adverse Events Medicine: abacavir, Condition: Infection, Human Immunodeficiency Virus, Phase: 4, Clinical Study ID: CNA106030, Sponsor: ViiV

Serious adverse events_LAIS grass tablets by allergic rhinoconjunctivitis EudraCT-Nr. 2012-004916-79 - Documentation serious adverse events

- 28-01-16 - 1 Formulier, 3 Itemgroepen, 17 Data-elementen, 1 Taal

Itemgroepen: Patient information, Serious adverse events, Medication

Study part: Documentation serious adverse events. Effectiveness and tolerance of sublingual desensitization with LAIS grass tablets in Patients with an allergic rhinoconjunctivitis caused by grass pollen. A prospective, multi-center, doubleblind, randomized, placebo-controlled Phase III study. Principal Investigator Prof. Dr. med. Ralph Mösges.

Adverse events_LAIS grass tablets by allergic rhinoconjunctivitis_EudraCT-Nr.2012-004916-79Test Study - Documentation adverse events

- 28-01-16 - 1 Formulier, 1 Itemgroep, 11 Data-elementen, 1 Taal

Itemgroep: adverse event

Study part: Documentation adverse events. Effectiveness and tolerance of sublingual desensitization with LAIS grass tablets in Patients with an allergic rhinoconjunctivitis caused by grass pollen. A prospective, multi-center, doubleblind, randomized, placebo-controlled Phase III study. Principal Investigator Prof. Dr. med. Ralph Mösges.

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.